Attention-Deficit/Hyperactivity Disorder

Stressed anxious man.

Viloxazine Under Review for ADHD Treatment in Adults

The Food and Drug Administration has accepted for review the supplemental New Drug Application for viloxazine extended-release for the treatment of attention-deficit hyperactivity disorder in adults. The application is supported by data from a multicenter, randomized, double-blind, placebo-controlled phase 3 trial ( Identifier: NCT04016779), which assessed the efficacy and safety of viloxazine in 374 adults…